Kura Oncology launches Caspian Therapeutics with $50 million financing
The new subsidiary aims to advance menin inhibitors for diabetes. Preclinical data shows potential beta-cell regeneration and improved insulin production.
See the latest news and media coverage for Kura. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing precision cancer medicines
kuraoncology.comLast updated
In short: Kura Oncology launched Caspian Therapeutics and achieved FDA approval and commercial growth for its leukemia drug, KOMZIFTI.
The new subsidiary aims to advance menin inhibitors for diabetes. Preclinical data shows potential beta-cell regeneration and improved insulin production.
She brings over twenty years of biopharmaceutical finance experience from Eli Lilly and Soleno Therapeutics to lead capital allocation strategies.
The board approved nonstatutory options totaling 48,450 shares at $12.89 per share for four new employees. These awards vest over four years to attract key talent.
KOMZIFTI generated $9.1 million in net product revenue, a 57% increase from Q1, with 115 new patient starts. Cash stood at $519 million plus $180 million in anticipated collaboration payments.
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. | Kura Oncology has...
An announcement from Kura Oncology ( ) is now available. Effective September 8, 2026, Kura Oncology appointed industry veteran Jennifer Fulk as Chief Financial Officer...
Shares of Kura Oncology KURA have gained 37.6% over the past month compared with the industry's 9.1% growth, driven primarily by improving investor confidence in...
On August 25, 2026, Kura Oncology Inc (KURA) saw a significant pre-market price jump of 8.6%,...
Track Kura and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kura and other trending companies.